Though recent phase III trials demonstrated a PFS and even an overall survival benefit for CDK4/6 inhibitors for advanced HR+/HER2- breast cancer in the first or second-line setting [13, 14], there is limited evidence to inform their CNS-specific activity. Here, ERBB2 is linked to breast cancer.